GISTour '09 (Global Interdisciplinary Specialists Training around the World) on 19 March and NET Tour '09 on 20 March, interactive road-shows sponsored by Novartis Oncology, will present to the region's medical community the latest results involving state-of-the-art GIST and NET treatment and management in patients.
Physicians will review data on the latest clinical research on prescription medication involving the use of imatinib to treat GIST and the use of octreotide to treat NET. Reflecting the multidisciplinary aspect of GIST and NET management, invited attendees include medical oncologists, surgical oncologists, gastroenterologists, radiologists and pathologists.
Gastrointestinal stromal tumors (GIST) belong to a group of cancers known as soft tissue sarcomas, and, as the most common sarcomas, they can be found most often in the stomach and small intestine. Neuroendocrine tumors (NET) can be found in the digestive system, yet they can arise in other parts of the body such as the lungs and the pancreas.
Browse
related articles
Doctors to discuss improved treatments for gulf patients with gastrointestinal tumors
- United Arab Emirates: Monday, March 16 - 2009 at 13:10
- PRESS RELEASE
Gulf-based doctors will discuss the update in the management and treatment of patients with gastrointestinal stromal tumors (GIST) or neuroendocrine tumors (NET) at upcoming gatherings of medical professionals.
Related stories
Also consider reading:
Digg
Facebook
LinkedIn
Twitter
Browse
related articles
Today's most read articles:
- » Boeing pushes 777 fix
- » Turki AL Shahrani appointed Director of Sales and Marketing for Riyadh Marriott
- » O2 Network celebrates the year's successes at fourth annual gathering in Dubai
- » Fitch: UAE banking sector can absorb bad loan increase
- » Khorfakkan performs record 343 moves per hour on UASC's 'Deira'
Log in to request more information from Novartis
Posted by Nadeen El AjouMonday, March 16 - 2009 at 13:10 UAE local time (GMT+4)
Replication or redistribution in whole or in part is expressly prohibited without the prior written consent of AME Info FZ LLC / Emap Limited.
Disclaimer:
Articles in this section are primarily provided directly by the companies appearing or PR agencies which are solely responsible for the content. The companies concerned may use the above content on their respective web sites provided they link back to http://www.ameinfo.com
Any opinions, advice, statements, offers or other information expressed in this section of the AMEinfo.com Web site are those of the authors and do not necessarily reflect the views of AME Info FZ LLC / Emap Limited. AME Info FZ LLC / Emap Limited is not responsible or liable for the content, accuracy or reliability of any material, advice, opinion or statement in this section of the AMEinfo.com Web site.
For details about submitting your stories, please read the guide - all content published is subject to our terms and conditions
It looks like you are using a Mac - check out our 
Web Feeds